A phase 1 trial of imatinib mesylate in combination with daunorubicin and cytarabine for patients for c-kit positive relapsed acute myeloid leukemia (AML)

被引：0
|
作者：
Advani, Anjali S. [1 ]
Sobecks, Ronald [1 ]
Sekeres, Mikkael A. [1 ]
Copelan, Ed [1 ]
Bates, Jennifer [1 ]
Tripp, Barbara [1 ]
Salvado, August [2 ]
Kalaycio, Matt [1 ]
机构：
[1] Cleveland Clin, Leukemia Program, Cleveland, OH USA
[2] Novartis Pharmaceut, E Hanover, NJ USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.906.906
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
906
引用
收藏
页码：276A / 276A
页数：1
相关论文
共 50 条
  • [21] Phase 1 Study of Alvocidib (DSP-2033) in Combination with Cytarabine/Mitoxantrone (ACM) or Cytarabine/Daunorubicin (A+7+3) in Japanese Patients (Pts) with Acute Myeloid Leukemia (AML)
    Morita, Yasuyoshi
    Ikezoe, Takayuki
    Ando, Kiyoshi
    Onozawa, Masahiro
    Yamane, Takahisa
    Hosono, Naoko
    Kiguchi, Toru
    Iwasaki, Hiromi
    Miyamoto, Toshihiro
    Kasai, Miho
    Sugimoto, Saori
    Miyazaki, Yasushi
    Kizaki, Masahiro
    Akashi, Koichi
    BLOOD, 2020, 136
  • [22] A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/ Refractory Acute Myeloid Leukemia (AML): Final Results
    Advani, Anjali S.
    Cooper, Brenda W.
    Visconte, Valeria
    Elson, Paul
    Chan, E. Ricky
    Carew, Jennifer
    Mukherjee, Sudipto
    Gerds, Aaron T.
    Carraway, Hetty E.
    Nazha, Aziz
    Hamilton, Betty K.
    Sobecks, Ronald
    Caimi, Paolo
    Tomlinson, Benjamin
    Malek, Ehsan
    Little, Jane A.
    Fensterl, Jaime
    Unger, Allison
    Zimmerman, Cassie
    Goebel, Christopher
    Hoxha, Nita
    Siebenaller, Caitlin
    Thomas, Jenna
    Rush, Mary Lynn
    Bogati, Samjhana
    Parsons, Eric
    Diligente, Rachael
    Kane, Donna
    Nielsen, Alek
    Hirsch, Cassandra M.
    Edelheit, Simone
    Miron, Alexander
    Pink, John
    Maciejewski, Jaroslaw P.
    Kalaycio, Matt
    De Lima, Marcos
    Sekeres, Mikkael A.
    BLOOD, 2017, 130
  • [23] Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia
    Kindler, T
    Breitenbuecher, F
    Marx, A
    Beck, J
    Hess, G
    Weinkauf, B
    Duyster, J
    Peschel, C
    Kirkpatrick, CJ
    Theobald, M
    Gschaidmeier, H
    Huber, C
    Fischer, T
    BLOOD, 2004, 103 (10) : 3644 - 3654
  • [24] Phase I study of Debio1143 (AT406) in combination with daunorubicin (D) and cytarabine (C) in patients with poor-risk acute myeloid leukemia (AML).
    DiPersio, John F.
    Erba, Harry Paul
    Larson, Richard A.
    Luger, Selina M.
    Mangan, Kenneth Francis
    Tallman, Martin S.
    Brill, Jeffrey Mark
    Vuagniaux, Gregoire
    Rouits, Elisabeth
    Zanna, Claudio
    Sorensen, J. Mei
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [25] A Phase II of Combination Daunorubicin and Cytarabine (Ara-C) and Nilotinib (TASIGNA) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression: Final Results
    Al-Kali, Aref
    Tibes, Raoul
    Palmer, Jeanne
    Alkhateeb, Hassan B.
    Patnaik, Mrinal M.
    Begna, Kebede H.
    Gangat, Naseema
    Atherton, Pamela
    Liu, Shujun
    He, Rong
    Hashmi, Shahrukh K.
    Litzow, Mark R.
    BLOOD, 2018, 132
  • [26] Experience with imatinib in a paediatric patient with C-kit positive refractory acute myeloid leukaemia
    Andres, M. M.
    Moreno, L.
    Bautista, F. J.
    Fernandez Navarro, J. M.
    Fernandez Sanmartin, M.
    Verdeguer, A.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S435 - S436
  • [27] Interim results of a multicenter phase I/II trial of the combination of imatinib mesylate with mitoxantrone/etoposide and cytarabine in patients with chronic myeloid leukemia in myeloid blast crisis.
    Fruehauf, S
    Topaly, J
    Buss, EC
    Fischer, T
    Emmerich, B
    Gschaidmeier, H
    Hehlmann, R
    Ho, AD
    Hochhaus, A
    BLOOD, 2003, 102 (11) : 255B - 255B
  • [28] Preliminary Results From a Phase III Trial of Imatinib Versus Imatinib in Combination with Cytarabine in Patients with First Chronic phase Myeloid Leukemia
    Thielen, Noortje
    van der Holt, Bronno
    Cornelissen, Jan J.
    Ammerlaan, Rianne
    Sonneveld, Pieter
    Kersten, Marie Jose
    Falkenburg, J. H. Frederik
    Sinnige, Harm
    Schipperus, Martin
    Schattenberg, Anton
    Kooy, Marinus van Marwijk
    Smit, Willem
    Verhoef, Gregor
    Chu, Isabel
    Valk, Peter
    Janssen, Jeroen J. W. M.
    Ossenkoppele, Gert
    BLOOD, 2011, 118 (21) : 1186 - 1186
  • [29] Relapsed and Refractory Acute Myeloid Leukemia (AML) Treated with AS1411 and Cytarabine: A Randomized Phase II Trial.
    Stuart, Robert Kenneth
    Acton, Gary
    BLOOD, 2008, 112 (11) : 676 - 676
  • [30] A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia
    Lancet, Jeffrey E.
    Roboz, Gail J.
    Cripe, Larry D.
    Michelson, Glenn C.
    Fox, Judith A.
    Leavitt, Richard D.
    Chen, Tianling
    Hawtin, Rachael
    Craig, Adam R.
    Ravandi, Farhad
    Maris, Michael B.
    Stuart, Robert K.
    Karp, Judith E.
    HAEMATOLOGICA, 2015, 100 (02) : 231 - 237
12345